A Koman1,2, R Bränström3, Y Pernow2, R Bränström3, I-L Nilsson1,2. 1. Department of Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden. 2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 3. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Primary hyperparathyroidism (pHPT) can be associated with potentially reversible cognitive impairment, which is occasionally mistaken for natural ageing and dementia. The aim was to evaluate short-term medical normalization of hypercalcaemia in surgical decision-making for elderly patients with mild cognitive deficiency. METHODS: Patients with pHPT were included in a prospective observational study. A test panel including the Montreal Cognitive Assessment (MoCA) and validated tools for estimation of psychological status (Hospital Anxiety and Depression Scale, HADS), and muscle strength (timed-stands test, TST) was applied at baseline, after 4 weeks of calcimimetic treatment, and after parathyroidectomy. Mild cognitive impairment was defined by a MoCA score below 26. A longitudinal increase in MoCA score of at least 2 points 6 months after surgery was considered clinically meaningful. RESULTS: Of 110 patients who underwent testing, 35 aged 50 years or more were identified to have mild cognitive dysfunction, including 19 who were aged at least 70 years (median MoCA score 23, i.q.r. 21-24). Calcimimetic treatment resulted in normalization of calcium levels, and improvements in MoCA and HADS scores, and TST time. Normal MoCA scores (at least 26) were reached in 17 patients by 6 months after surgery, of whom 10 were aged 70 years or older. Long-term increase in MoCA score correlated with the decrease in ionized calcium concentration (r = -0.536, P = 0.022). Baseline calcium concentration and improvement in MoCA with calcimimetic treatment were identified as independent predictors of favourable outcome after parathyroidectomy. CONCLUSION: Medical normalization of hypercalcaemia can aid in predicting outcome after parathyroidectomy.
BACKGROUND: Primary hyperparathyroidism (pHPT) can be associated with potentially reversible cognitive impairment, which is occasionally mistaken for natural ageing and dementia. The aim was to evaluate short-term medical normalization of hypercalcaemia in surgical decision-making for elderly patients with mild cognitive deficiency. METHODS: Patients with pHPT were included in a prospective observational study. A test panel including the Montreal Cognitive Assessment (MoCA) and validated tools for estimation of psychological status (Hospital Anxiety and Depression Scale, HADS), and muscle strength (timed-stands test, TST) was applied at baseline, after 4 weeks of calcimimetic treatment, and after parathyroidectomy. Mild cognitive impairment was defined by a MoCA score below 26. A longitudinal increase in MoCA score of at least 2 points 6 months after surgery was considered clinically meaningful. RESULTS: Of 110 patients who underwent testing, 35 aged 50 years or more were identified to have mild cognitive dysfunction, including 19 who were aged at least 70 years (median MoCA score 23, i.q.r. 21-24). Calcimimetic treatment resulted in normalization of calcium levels, and improvements in MoCA and HADS scores, and TST time. Normal MoCA scores (at least 26) were reached in 17 patients by 6 months after surgery, of whom 10 were aged 70 years or older. Long-term increase in MoCA score correlated with the decrease in ionized calcium concentration (r = -0.536, P = 0.022). Baseline calcium concentration and improvement in MoCA with calcimimetic treatment were identified as independent predictors of favourable outcome after parathyroidectomy. CONCLUSION: Medical normalization of hypercalcaemia can aid in predicting outcome after parathyroidectomy.
Authors: Dolores M Shoback; John P Bilezikian; Stewart A Turner; Laura C McCary; Matthew D Guo; Munro Peacock Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: S Bannani; N Christou; C Guérin; A Hamy; F Sebag; M Mathonnet; P Guillot; C Caillard; C Blanchard; E Mirallié Journal: Br J Surg Date: 2018-02 Impact factor: 6.939
Authors: Bian Wu; Philip I Haigh; Roy Hwang; Philip H G Ituarte; In-Lu Amy Liu; Theodore J Hahn; Michael W Yeh Journal: J Clin Endocrinol Metab Date: 2010-07-07 Impact factor: 5.958
Authors: Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty Journal: JAMA Surg Date: 2016-10-01 Impact factor: 14.766
Authors: J C Dalrymple-Alford; M R MacAskill; C T Nakas; L Livingston; C Graham; G P Crucian; T R Melzer; J Kirwan; R Keenan; S Wells; R J Porter; R Watts; T J Anderson Journal: Neurology Date: 2010-11-09 Impact factor: 9.910
Authors: John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: Michael W Yeh; James E Wiseman; Philip H G Ituarte; Jesse D Pasternak; Roy S Hwang; Bian Wu; In-Lu Amy Liu; Philip I Haigh Journal: Ann Surg Date: 2012-06 Impact factor: 12.969